The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of FPHL.
This 6-month, double-blind, placebo-controlled, 1:1 randomized clinical trial investigates whether daily supplementation with Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.
Women aged 50-65.
Volunteers with initial FPHL. (Images will be sent to a dermatologist for assessment).
Commitment not to use systemic, topical, or oral products with an effect similar to that of the product to be evaluated throughout the study period.
Do not change the daily routine regarding the use of cosmetic products and eating habits.
Allergy or reactivity to some of the components of the product, or a product with similar category than tested one.
Women who have undergone dermatological treatment for hair loss (PRPs, mesotherapy, etc.) or hair transplant.
Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate severe seborrheic dermatitis, eczema, cancer, etc.
Women who present alopecia because of a medical illness (hypothyroidism, anemia, lupus, etc.).